Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group.
Impact in
- Epidemiology 371
Classified as
- Journal
- PubMed
In The Last Decade
doi.org/w30723352 →Countries where authors are citing Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group.
This map shows the geographic impact of Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group.. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. more than expected).
Fields of papers citing Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group.
This network shows the impact of Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group.. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group..
About Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group.
This paper, published in 1989, received 513 indexed citations . Written by R C Bone, Charles J. Fisher, T. P. Clemmer and R.A. Balk covering the research area of Epidemiology, Critical Care and Intensive Care Medicine and Endocrinology, Diabetes and Metabolism. It is primarily cited by scholars working on Epidemiology (371 citations), Critical Care and Intensive Care Medicine (150 citations), Immunology (123 citations), Pulmonary and Respiratory Medicine (99 citations) and Surgery (90 citations). Published in PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/w30723352.